What else is available?
The CTSC offers seed funding opportunities for pilot studies and community engagement research. RFAs for all award types are released on specific date each year and announced through the CTSC web site as well as broadcast e-mail at each of the partner institutions. Descriptions of the individual award types, as well as links to the latest request for applications and review criteria, are provided under the quick access area.
Effective collaboration between basic and clinical researchers is the central engine for advancing biomedical innovation. The objective of Pilot Awards program is to create opportunities for translational team research across disciplines and institutions, and between basic and clinical scientists. Funding is provided for up to two years. Priority is given to proposals with:
Emphasis on drug discovery, targeted therapeutics, biomarker or device development and novel technologies. Team Orientation; translational focus; pre-clinical studies should have near-term potential to translate into patient- oriented research; clinical trials (phases I & II).
Community Engagement Awards
The aim of the Community Engagement Award program is to foster research and collaborations focusing on community engagement which have a direct relevance to community health concerns. Funding is provided for one year. Priority is given to proposals with:
Strong community focus with a clear goal of facilitating the transfer of evidence-based practice. Fostering collaboration between the community, CTSC institutions and affiliates with emphasis on comparative effectiveness research and health disparities research.
Novel Technology Team Award
The aim of the Novel Technology Team Award program is for teams of clinical investigators, biomedical engineers, and business faculty to develop a novel medical technology with potential to rapidly translate into a product that improves human health. Funding is provided for one year.
Examples of proposal topics include: biomedical materials and regenerative medicine; biomedical devices; biomedical drugs; biomedical imaging and computational modeling; combination products for biomedical applications. Evaluation criteria include: innovation and scientific merit, potential health care impact, technical feasibility, and potential for commercialization.